Science Friday Talks

KCU-Kansas City

Get up-to-the-minute research discoveries on hot topics, such as Alzheimer’s disease, biological warfare and cancer.

Science Friday Talks

KCU-Kansas City

Get up-to-the-minute research discoveries on hot topics, such as Alzheimer’s disease, biological warfare and cancer.

MiR-290 Cluster is an Effective Oct4 Substitute for Reprogramming Skeletal Myoblasts

Dr. Yi‐Gang Wang, Director, Regenerative Medicine Research; Professor, Department of Pathology and Laboratory Medicine, University of Cincinnati

Thursday, Dec. 1, 2016

Dybedal, Room 240

Kansas City, Mo.

Talk Summary - Induced pluripotent stem cells (iPSCs) have emerged as a promising resource for autologous cell-based treatments. However, widespread clinical applications are still limited by the source of somatic cells and low reprogramming efficiency. Skeletal myoblasts (SkM) have arisen as an ideal candidate somatic cell for reprogramming due to its inherited myogenic properties and the associated expression pattern of endogenous pluripotent gene programming.

Reprogramming of SkMs through introduction of the miR-290 cluster is an efficient means of promoting iPS cell production. Moreover, this miRNA cluster can replace the reprogramming master gene Oct4 to initiate somatic cell reprogramming. These results demonstrate that both miR-291a-5p and miR-291b-5p can directly target Pax7 (a myogenic marker) to enhance the iPSC generation.

Given the two roles of this miRNA cluster in somatic cell reprogramming and iPS cell pre-differentiation, the miR-290-295 derived SiPSC could be an important regulator to manipulate cardiomyocyte generation. These discoveries will facilitate elucidation of the molecular mechanisms that underlie the reprogramming process and has potential therapeutic use in the fields of biomedical research and regenerative medicine.

Bio - Over the past two decades, Dr. Wang's research in cardiovascular pathophysiology and therapies has focused on three areas:

  1. effect of various additive agents of cardioplegic solution on functional cardiac restoration
  2. ischemic preconditioning against ischemia/reperfusion injury, its molecular mechanisms and signaling pathways
  3. progenitor cell based cell therapy for treatment of myocardial infarction.

The goal of Dr. Wang's projects as a collective and unified research and discovery program is to identify and develop new strategies that enhance the application of cell-based therapies for myocardial tissue regeneration.